Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures: 2016-2024

Historic Gains from Sales and Divestitures for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $967,773.

  • Collegium Pharmaceutical's Gains from Sales and Divestitures rose 4.32% to $980,992 in Q3 2025 from the same period last year, while for Sep 2025 it was $980,992, marking a year-over-year increase of 4.32%. This contributed to the annual value of $967,773 for FY2024, which is 43.24% up from last year.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures amounted to $967,773 in FY2024, which was up 43.24% from $675,647 recorded in FY2023.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures' 5-year high stood at $967,773 during FY2024, with a 5-year trough of $335,524 in FY2020.
  • For the 3-year period, Collegium Pharmaceutical's Gains from Sales and Divestitures averaged around $738,875, with its median value being $675,647 (2023).
  • Data for Collegium Pharmaceutical's Gains from Sales and Divestitures shows a peak YoY soared of 71.06% (in 2020) over the last 5 years.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures (Yearly) stood at $335,524 in 2020, then skyrocketed by 32.56% to $444,769 in 2021, then rose by 28.88% to $573,204 in 2022, then rose by 17.87% to $675,647 in 2023, then spiked by 43.24% to $967,773 in 2024.